Defendant
4 cases as defendant.
IPR filed by Sun Pharmaceutical Industries challenging the '405 patent; joined with IPR2017-00854 and finalized by written decision.
IPR by Actavis Elizabeth and Teva challenging the '405 patent was joined with IPR2017-00854 and terminated with the Final Written Decision on 2018-07-11.
IPR challenging the '405 patent was instituted and joined into lead IPR2017-00854; final written decision issued and latest docket activity was 2018-08.
IPR challenging claims 1-6 of the '405 patent. The PTAB instituted review and issued a Final Written Decision holding all claims not shown unpatentable; IPR certificate issued 2020-02-10.